【論文】

Kumada H,Suzuki Y,Karino Y,Chayama K,Kawada N,Okanoue T,Itoh Y,Mochida S,Toyoda H,Yoshiji H,Takaki S,Yatsuzaka N,Yodoya E,Iwaza T,Fujimoto G,Robertson MN,Black S,Cari L,Waji J. The combination of elbasvir and grazoprevir and ofr the treatment of chromic HCV infection in Japanese patients:a randomized phase Ⅱ/Ⅲ study. J Gastroenterol(52) 520-533 2017

Kumada H,Koike K,Suyama K,Ito H,Itoh H,Sugiura W. Efficacy and safety of tenofovir disoproxil fumarate rescue therapy for chronic hepatitis B patients who failed other uncleos(t)ide analogues. Hepatol Res doi: 10.1111/hepr.12842 2017

Kumada H,Miyakawa H,Muramatsu T,Ando N,Oh n,Takamori K,Nakamoto H. Efficacy of nalufurafine hydrochloride in patients with chronic liver disease with refractory pruritus:a randomized,double-blind trial. Hepatol Res doi 10.1111/hepr.12830 2017

Kumada H,Suzuki F,Kamiya N,Orihashi M,Nakayasu Y,Yamada I. Efficacy and safety of telaprevir with pegylated interferon α-2a and ribavirin in Japanese patients. Hepatol Res doi 10.1111/hepr.12722 2017

Kumada H,Suzuki Y,Karino Y,Chayama K,Kawada N,Okanoue T,Itoh Y,Mochida S,Toyoda H,Yoshiji H,Takaki S,Yatsuzaka N,Yodoya E,Iwaza T,Fujimoto G,Robertson MN,Black S,Cari L,Waji J. The combination of elbasvir and grazoprevir and ofr the treatment of chromic HCV infection in Japanese patients:a randomized phase Ⅱ/Ⅲ study. J Gastroenterol(52) 520-533 2017

Kumada H,Mochida S,Suzuki F,Chayama K,Karino Y,Nakamura K,Fujimoto G,Howe AY,Ludmerer SW,Mobashery N. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1(GT1b)infection:phase 3 studies. J Gastroenterol Hepatol(31) 1674-1683 2016

Kumada H,Suzuki F,Suzuki Y,Toyota J,Karino Y,Chayama K,Kawakami Y,Fujiyama S,Ito T,Itoh Y,Tamura E,Ueki T,Ishikawa H,Wenhua Hu,Fiona McPhee,Misti Linaberry,Eric Hughes. Randomized comparison of daclatasvir+asunaprevir versus telaprevir+peginterferon/ribavirin in Japanese HCV patients. J Gastroenterol Hepatol(31) 14-22 2016

Kumada H, Chayama K, Lino Rodrigues-Jr, Suzuki F, Ikeda K, Toyoda H, Sato K, Karino Y, Matsuzaki Y, Kioka K, Carolyn Setze, Tami Pilot-Matias, Meenal Patwardhan, Regis A Vilchez, Margaret Burroughs, Rebecca Redman. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology(62) 1037-1046 2015

Kumada H,Hayashi N,Izumi N,Okanoue T,Tsubouchi H,Yatsuhashi H,Kato M,Rito K,Kodama Y,Seto C,Goto S. Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype1 hepatitis C virus infection: The CONCERTO-4 study. Hepatol Res(45) 501-513 2015

Kumada H,Motoura H,Okuni K,SNMC Post Marketing Study Group,Shii K. Post-marketing Study of Stronger Neo-Minophagen C for Elderly Patients with Chronic Hepatitis C -A prospective Study- Geriat.Med.53(5) 505-520 2015

Kumada H,Sato K,Takehara T,Nakamura M,Ishigami M,Chayama K,Toyota J,Suzuki F,Nakayashu Y,Ochi M,Yamada I,Okanoue T. Efficacy of telaprevir-based therapy for difficulit-to-treat patients with genotype 2 chronic hepatitis C in Japan. Hepatol Res(45) 745-754 2015

Akuta N,Sezaki H,Suzuki F,Fujiyama S,Hosaka T,Kobayashi M,Kobayashi M,Saitoh S,Suzuki Y,Arase Y,Ikeda K,Kumada H. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype1 failures to prior NS5A inhibitors regimens. J Med Virol, 89(7) , 1248-54, 2017

Akuta N,Sezaki H,Suzuki F,Fujiyama S,Kawamura Y,Hosaka T,Kobayashi M, Kobayashi M,Saitoh S,Suzuki Y,Arase Y,Ikeda K,Kumada H. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan. J Med Virol, 89(2), 284-90, 2017

Akuta N,Sezaki H,Suzuki F,Kawamura Y,Hosaka T,Kobayashi M,Saitoh S,Sezaki H,Akuta N,Suzuki F,Suzuki Y,Arase Y,Kumada H. Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older. J Med Virol, 89(1), 91-8, 2017

Kawamura Y,Ikeda K,Fujiyama S,Hosaka T,Kobayashi M,Saitoh S,Sezaki H,Akuta N, Suzuki F,Suzuki Y,Arase Y,Kumada H. Usefulness and limitation of balloon-occluded transcatheter arterial chemoembolization using miriplatin for patients with 4 or less hepatocellular carcinoma nodules. Hepatol Res, 47(4), 338-46, 2017

Kawamura Y,Ikeda K,Fujiyama S,Hosaka T,Kobayashi M,Saitoh S,Sezaki H,Akuta N,Suzuki F,Suzuki Y,Arase Y,Kumada H. Potential of a no-touch pincer ablation procedure that uses a multipolar radiofrequency ablation system to prevent intra-subsegmental recurrence of small and single hepatocellular carcinomas. Hepatol Res doi: 10.1111/hepr.12838 2017

Kobayashi M,Suzuki F,Fujiyama S,Kawamura Y,Sezaki H,Hosaka T,Akuta N,Suzuki Y,Saitoh S,Arase Y,Ikeda K,Kumada H. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carconoma in patients with HCV infection. J Med Virol, 89(3), 476-83, 2017

Suzuki F,Suzuki Y,Hosaka T,Sezaki H,Akuta N,Fujiyama S,Kawamura Y,Kobayashi M,Saitoh S,Arase Y,Ikeda K,Kobayashi M,Mineta R,Suzuki Y,Kumada H. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to uncleoside/uncleotide analogs. J Gastroenterol, 52(5), 641-51, 2017

Osawa M, Akuta N, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Suzuki Y, Ikeda K, Kumada H. Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus. J Med Virol doi: 10.1002/jmv.24890 2017

Ogata F, Kobayashi M, Akuta N, Osawa M, Fujiyama S, Kawamura y, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H. Outcome of all-oral direct-acting antiviral regimens on the rate of development of hepatocellular carcinoma in patients with hepatitis C virus genotype 1-related chronic liver disease. Oncology doi:10.1159/000470910 2017

Akuta N, Kumada H, Fujiyama S, Sezaki H,Suzuki F, Hosaka T,Kobayashi M,Kobayashi M,Saitoh S,Suzuki Y,Arase Y,Ikeda K. Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride. Hepatol Res doi:10.111/hepr.12894 2017

Sezaki H, Suzuki F, Hosaka T, Akuta N, Fujiyama S, Kawamura Y, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings. Liver INT doi:10.1111/liv.13384 2017

Akuta N,Kawamura Y,Suzuki F,Saitoh S,Arase Y,Fujiyama S,Sezaki H,Hosaka T,Kobayashi M,Suzuki Y,Kobayashi M,Ikeda K,Kumada H. Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. BMC, Gastroenterol (16), 141-50, 2016

Kunimoto H,Ikeda K,Sorin Y,Fujiyama S,Kawamura Y,Kobayashi M,Sezaki H,Hosaka T,Akuta N,Saitoh S,Suzuki F,Suzuki Y,Arase Y,Kumada H: Long-term outcomes of hepatitis-C-infected patients achieving a sustained virological response and undergoing radical treatment for hepatocellular carcinoma. Oncology, (90), 167-75, 2016.

Tanaka T,Ikeda K,Sorin Y,Fukushima T,Kawamura Y,Kobayashi M,Kumada H. Three-Dimensional imaging using contrase-enhanced and three-dimensional ultrasound techniques in the ablative zone treated with a multipolar radiofrequency ablation system for hepatocellular carcinoma. Oncology, 90(5), 255-60, 2016.

Akuta N,Kobayashi M,Suzuki F,Sezaki H,Fujiyama S,Kawamura Y,Hosaak T,Kobayashi M,Saitoh S,Suzuki Y,Arase Y,Ikeda K,Kumada H: Liver fibrosis and body mass index predict hepatocarcinogenesis following eradication of hepatitis C virus RNA by direct-acting antivirals.Oncology(91),341-347,2016.

Akuta N,Kawamura Y,Arase Y,Suzuki F,Sezaki H,Hosaka T,Kobayashi M,Kobayashi M,Saitoh S,Suzuki Y,Ikeda K,Kumada H: Relationships between genetic variations of PNPLA3,TM6SF2 and Histological features of nonalcoholic fatty liver disease in Japan.Gut Liver(10),437-445,2016.

Akuta N, Sezaki H, Suzuki F, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y,Arase Y, Ikeda K, Kumada H: Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.J Med Virol(88),506-511,2016.

Kawamura Y,Arase Y,Ikeda K,Akuta N,Kobayashi M,Saitoh S,Suzuki F,Suzuki Y,Inao M,Mochida S,,Kumada H: Effects of alcohol consumption on hepatocarcinogensis in Japanese Patients with fatty liver disease.Clinical Gastroenterrology and Hepatology(14),597-605,2016.

Akuta N,Kawamura Y,Suzuki F,Saitoh S,Arase Y,Kunimoto H,Sorin Y,Fujiyama S,Sezaki H,Hosaka T,Kobayashi M,Suzuki Y,Komayashi M,Ikeda K,Kumada H. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalvoholic fatty liver disease in Japan.Hepatol Int(10),647-656,2016.